GlobeNewswire by notified

GlucoModicum publishes first-in-human data assessing the safety and effectiveness of its MHD technology for accurate needle-free glucose monitoring


To view this piece of content from, please give your consent at the top of this page.

GlucoModicumpublishes first-in-human data assessing the safety and effectiveness ofits MHD technologyfor accurate needle-free glucose monitoring

  • Human data shows high correlation between concentration of glucose in samples extracted with MHD technology against capillary blood glucose samples with MARD of 12.9%
  • Subsequent improvements post-trial have resulted in MARD of <9%
  • Results further validate MHD for accurate needle-free continuous glucose monitoring
  • Significant progress made in product development of Talisman with Philips-Medisize, a world leader in MedTech design and development

Helsinki, Finland, 09November 2022 – GlucoModicum, a company transforming glucose monitoring with precise, needle-free magnetohydrodynamic (MHD) technology, announces that peer-reviewed data from the first-in-human study assessing the safety and effectiveness of its proprietary MHD technology for needle-free measuring of glucose levels has been published in Scientific Reports, part of the Nature Research portfolio.

Data drawn from glucose tolerance tests on healthy volunteers obtained a strong correlation between the concentration of glucose in interstitial fluid (ISF) samples extracted with GlucoModicum’s MHD technology against capillary blood glucose (CBG) samples.

The data obtained with MHD technology demonstrate a 12.9% MARD (Mean Absolute Relative Difference), a measure of the agreement between a glucose sensor reading and a reference blood glucose reading. This value lies within the range of 10-15% typically reported by commercially available CGM devices. Furthermore, no evidence of long-lasting effects on the skin were observed.

The results further validate data published in the journal Biosensors and Bioelectronics in April this year, which demonstrated that MHD integrated with a biosensor is a highly effective method for accurate determination of glucose concentrations. Additionally, GlucoModicum published data in Scientific Reports in 2021 showing that MHD extracts ISF from the skin 13x more effectively than other needle-free approaches. Taken in combination, these datasets validate the key building blocks of GlucoModicum’s technology offering: efficient extraction of ISF, strong correlation to blood glucose levels, and the integration of MHD with a biosensor in a small device. This provides a strong evidence base supporting the development of a non-invasive glucose monitor using GlucoModicum’s MHD platform technology.

Alejandro García, Chief Technology Officer of GlucoModicum, commented: The benefits of continuous glucose monitoring in diabetes management are well documented, but broader adoption of CGM systems is limited by their cost and invasiveness.These results, the first from research conducted inhumans, highlight the efficacy of our proprietary MHD technology in extracting interstitial fluid through the skin,along withdemonstrating the accuracy of our approach. Recent improvements in our technology have enabled us to obtainMARD values of <9%, demonstrating an accuracy beyond many commercial, invasive CGMs.

GlucoModicum is pleased to provide an update on the product development of the Talisman, the Company’s proprietary non-invasive CGM which uses MHD technology. In close collaboration with Philips-Medisize, GlucoModicum’s design and development partner, the Talisman continues to be developed to ensure usability and manufacturability of the final prototype.

The publication is available online on Scientific Reports here:

Image: Prototype of the Talisman, a non-invasive continuous glucose monitor

To view this piece of content from, please give your consent at the top of this page.

- END -

About GlucoModicum

GlucoModicum is transforming glucose monitoring with precise, needle-free magnetohydrodynamic technology. Its proprietary platform has the potential to radically change how people monitor their health, creating solutions that are precise, accessible and needle-free, empowering people to live healthier lives. The company’s first product is a non-invasive, wearable glucose monitor for patients suffering from diabetes. GlucoModicum was founded in 2018 as a spinout of the University of Helsinki and combines an experienced, multi-disciplinary in-house team with world-class partners to deliver groundbreaking solutions for personal biomarker monitoring.

About Talisman

GlucoModicum’s magnetohydrodynamic (MHD) technology is currently being productized as the Talisman, the first new, truly non-invasive CGM technology in 25 years. The Talisman uses MHD to extract interstitial fluid (ISF) from the skin without the use of needles, enabling rapid, painless and accurate readings of glucose levels. Talisman addresses the needs of the ~500 million diabetics and ~500 million pre-diabetics globally, and serves as a tool to promote better health among the +2 billion people at risk of developing diabetes.

GlucoModicum is undertaking an ongoing device programme with Phillips-Medisize, a global leader in design and high-volume manufacturing of FDA approved diabetes care devices. The effectiveness and accuracy of GlucoModicum’s technology has been demonstrated in peer-reviewed studies assessing the efficiency of ISF extraction, biosensor compatibility and correlation of readings to blood glucose levels. Talisman will enter clinical studies in 2023.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech Shares Start Trading on Nasdaq Iceland Main Market8.12.2022 09:30:00 CET | Press release

Listing on the Main Market can increase visibility, which may allow the company to appear in both domestic and global indexesAlvotech became first dual-listed Icelandic company in the U.S. and Iceland after market debut in June, trading under the symbol “ALVO“Robert Wessman Founder and Executive Chairman will ring the Nasdaq Iceland closing bell at 15:30 GMT on December 8, 2022 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that trading in its shares will move from the Nasdaq Iceland First North Growth market (“First North”) to the Nasdaq Iceland Main Market (“Main Market”), starting today December 8, 2022. The “ALVO” stock market symbol for Alvotech remains unchanged and trade on the Nasdaq U.S. stock exchange is not affected. A Main Market listing in Iceland can increase a company’s visibility and, subject to meeting certain conditions, may result in inclusion in Icelandic and

Deep Energy Capital and Eavor Technologies to build 5 geothermal projects as construction gathers pace at their first European site8.12.2022 09:00:00 CET | Press release

LONDON and DUSSELDORF, Germany and CALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Deep Energy Capital, LLP (“Deep Energy”), an independent specialized renewable energy investment firm, and Eavor Technologies Inc. (“Eavor”), the preeminent advanced geothermal technology company, have agreed to develop, finance, construct and operate geothermal projects deploying Eavor’s advanced geothermal technology: Eavor-Loop™. Deep Energy will finance at least five projects, requiring up to €1 billion, from Eavor’s growing European and North American project pipeline. The projects will deliver continuous renewable power and heat and are expected to benefit from long-term feed-in-tariffs and fixed price off-take contracts underpinned by the growing value of resilient and local sources of clean energy. Eavor’s closed-loop geothermal systems extract heat energy from an isolated network of wellbores, akin to a deep underground radiator. Together, the five closed-loop projects are expected to genera

Changes in Bilia’s Group Management8.12.2022 09:00:00 CET | Press release

As of today, Bilia includes Carl Fredrik Ewetz in Group Management, Head of Investor Relations and M&A. Magnus Karlsson, CEO of Motorit AB, has resigned and has left the Group Management. Anna Höglund, who is currently Head of System Development at the Bilia Group’s IT company, Motorit AB, will be acting CEO of Motorit AB until a permanent solution is in place. Anna has a solid background from 11 years within Bilia where she has held various leading roles. Bilia’s Group Management consists of Per Avander, President and CEO, Stefan Nordström, Deputy CEO, Kristina Franzén, CFO, Frode Hebnes, CEO of Bilia Personbil AS, Norway, Elin Delvert, HR Director, Mathias Nilsson, CEO Bilia Personbilar AB, Anders Rydheimer, Communications Director CMO & CDO and Carl Fredrik Ewetz, Head of Investor Relations and M&A. Per Avander, Bilia's Managing director and CEO, comments: "Carl Fredrik is already working together with the Group Management, why this is not a major change but reflects a working metho

Förändringar i Bilias koncernledning8.12.2022 09:00:00 CET | Pressemelding

Bilia inkluderar från och med idag Carl Fredrik Ewetz i koncernledningen, chef Investerarrelationer och M&A. Magnus Karlsson, VD Motorit AB, har sagt upp sin anställning och lämnar koncernledningen. Anna Höglund, som idag är chef för systemutvecklingen på Biliakoncernens IT-bolag, Motorit AB, kommer att verka som tillförordnad VD för Motorit AB tills dess att en permanent lösning är på plats. Anna har en gedigen bakgrund med sina 11 år inom Biliakoncernen i vilken hon haft flera olika ledande roller. I Bilias koncernledning ingår Per Avander, VD och koncernchef, Stefan Nordström, vice VD, Kristina Franzén, CFO, Frode Hebnes, VD i Bilia Personbil AS, Norge, Elin Delvert, HR-direktör, Mathias Nilsson, VD Bilia Personbilar AB, Anders Rydheimer, Affärsutvecklings- och Kommunikationsdirektör och Carl Fredrik Ewetz, chef Investerarrelationer och M&A. Per Avander, Bilias VD och koncernchef, kommenterar: ”Carl Fredrik arbetar redan idag tillsammans med koncernledningen, varför detta inte är en

Press release: Lectra announces the acquisition of the majority of the capital of TextileGenesis8.12.2022 08:37:47 CET | Press release

Lectra announces the acquisition of the majority of the capital of TextileGenesis Lectra extends its software offer to material traceability and reinforces its position in Industry 4.0 Paris, December 8, 2022 - Lectraannounces the signature of an agreement to acquire 51% of the capital and voting rights of the Dutch company TextileGenesis. As a major player in the fashion, automotive, and furniture markets, Lectra contributes with boldness and passion to the Industry 4.0 revolution by providing software, equipment, data, and services to brands, manufacturers, and retailers. Founded in 2018, TextileGenesis provides a Software as a Service (SaaS) platform that enables fashion brands and sustainable textile manufacturers to ensure a reliable, secure and fully digital mapping of their textiles, from the fiber to the consumer, and thereby guarantee their authenticity and origins. This solution ensures the traceability of TextileGenesis’ customers' entire sustainable textile supply chain in